Krystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual MeetingBusiness Wire • 10/08/20
Krystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare ConferencesGlobeNewsWire • 09/09/20
Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic IndicationsGlobeNewsWire • 08/25/20
Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic FibrosisGlobeNewsWire • 08/17/20
Krystal Biotech Reports Second Quarter 2020 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 08/10/20
Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis BullosaGlobeNewsWire • 07/28/20
Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business DevelopmentGlobeNewsWire • 07/20/20
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common StockGlobeNewsWire • 05/19/20
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)GlobeNewsWire • 05/14/20
Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational ProgressGlobeNewsWire • 05/04/20
Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing FacilityGlobeNewsWire • 01/24/20
Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue?Zacks Investment Research • 12/03/19
Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to BuyZacks Investment Research • 11/14/19
Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. PatentGlobeNewsWire • 09/27/19
Krystal Biotech: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin DiseaseSeeking Alpha • 09/19/19
Krystal Clear: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin DiseaseSeeking Alpha • 09/19/19
Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (“TGM1”) Deficient Autosomal Recessive Congenital Ichthyosis (“ARCI”)GlobeNewsWire • 09/04/19
Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech ConferenceGlobeNewsWire • 08/27/19